Literature DB >> 27326336

Ferrocenyl 2,5-Piperazinediones as Tubulin-Binding Organometallic ABCB1 and ABCG2 Inhibitors Active against MDR Cells.

Anna Wieczorek1, Andrzej Błauż2, Janusz Zakrzewski3, Błażej Rychlik2, Damian Plażuk3.   

Abstract

The tubulin-microtubule system is a common target of many anticancer drugs. However, the use of chemotherapeutics frequently leads to the development of a clinically relevant phenomenon of multidrug resistance (MDR). One of the basic mechanisms involved in MDR involves elevated expression and/or activity of several ATP-binding cassette superfamily members (ABC transporters) which are normally responsible for the efflux of xenobiotics or secondary metabolites outside the cell. Here we present the synthesis and biological characteristics of ferrocenyl analogues of plinabulin, i.e. one of the so-called "spindle poisons". We found that replacement of the phenyl group of plinabulin by the ferrocenyl moiety turns this compound into a potent inhibitor of ABCB1 and ABCG2, thus making it possible to overcome the multidrug resistance phenomenon. We also demonstrated that the alkyl group attached to the imidazole moiety of ferrocenyl analogues of plinabulin strongly affects their potency to inhibit tubulin polymerization.

Entities:  

Keywords:  ABCB1 inhibitor; ABCG2 inhibitor; Ferrocene; bioorganometallic chemistry; cancer; multidrug resistance

Year:  2016        PMID: 27326336      PMCID: PMC4904264          DOI: 10.1021/acsmedchemlett.6b00046

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

1.  A series of unconjugated ferrocenyl phenols: prospects as anticancer agents.

Authors:  Elizabeth Hillard; Anne Vessières; Franck Le Bideau; Damian Plazuk; Daniela Spera; Michel Huché; Gérard Jaouen
Journal:  ChemMedChem       Date:  2006-05       Impact factor: 3.466

2.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

Review 3.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

Review 4.  The odyssey of marine pharmaceuticals: a current pipeline perspective.

Authors:  Alejandro M S Mayer; Keith B Glaser; Carmen Cuevas; Robert S Jacobs; William Kem; R Daniel Little; J Michael McIntosh; David J Newman; Barbara C Potts; Dale E Shuster
Journal:  Trends Pharmacol Sci       Date:  2010-04-02       Impact factor: 14.819

5.  Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative.

Authors:  Benjamin Kater; Andrea Hunold; Hans-G Schmalz; Lisa Kater; Birgit Bonitzki; Patrick Jesse; Aram Prokop
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-11       Impact factor: 4.553

6.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

Review 7.  Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.

Authors:  Iwao Ojima
Journal:  Acc Chem Res       Date:  2007-07-31       Impact factor: 22.384

8.  A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.

Authors:  Damian Plazuk; Anne Vessières; Elizabeth A Hillard; Olivier Buriez; Eric Labbé; Pascal Pigeon; Marie-Aude Plamont; Christian Amatore; Janusz Zakrzewski; Gérard Jaouen
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 9.  Multidrug resistance: Physiological principles and nanomedical solutions.

Authors:  Sijumon Kunjachan; Błażej Rychlik; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

10.  Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action.

Authors:  Faustine Dubar; Jamal Khalife; Jacques Brocard; Daniel Dive; Christophe Biot
Journal:  Molecules       Date:  2008-11-20       Impact factor: 4.411

View more
  3 in total

1.  Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins: Exploration of the N3 and N9 Positions and Interaction with Multidrug-Resistance Proteins.

Authors:  Ramesh Dasari; Andrzej Błauż; Derek C Medellin; Roaa M Kassim; Carlos Viera; Maximo Santarosa; Alet E van der Westhuyzen; Willem A L van Otterlo; Taryn Olivas; Tugba Yildiz; Tania Betancourt; Charles B Shuster; Snezna Rogelj; Błażej Rychlik; Todd Hudnall; Liliya V Frolova; Alexander Kornienko
Journal:  ChemMedChem       Date:  2019-01-25       Impact factor: 3.466

2.  ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.

Authors:  Dejun Jiang; Tailong Lei; Zhe Wang; Chao Shen; Dongsheng Cao; Tingjun Hou
Journal:  J Cheminform       Date:  2020-03-05       Impact factor: 5.514

3.  Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.

Authors:  Michał Łomzik; Muhammad Hanif; Aleksandra Budniok; Andrzej Błauż; Anna Makal; Daniel M Tchoń; Barbara Leśniewska; Kelvin K H Tong; Sanam Movassaghi; Tilo Söhnel; Stephen M F Jamieson; Ayesha Zafar; Jóhannes Reynisson; Błażej Rychlik; Christian G Hartinger; Damian Plażuk
Journal:  Inorg Chem       Date:  2020-10-01       Impact factor: 5.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.